Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

被引：25

作者：

Shields, Adrian M. ^{[1
]}

Anantharachagan, Ariharan ^{[2
]}

Arumugakani, Gururaj ^{[3
]}

Baker, Kenneth ^{[4
,5
]}

Bahal, Sameer ^{[6
]}

Baxendale, Helen ^{[7
]}

Bermingham, William ^{[8
]}

Bhole, Malini ^{[9
]}

Boules, Evon ^{[10
]}

Bright, Philip ^{[11
]}

Chopra, Charu ^{[12
]}

Cliffe, Lucy ^{[13
]}

Cleave, Betsy ^{[13
]}

Dempster, John ^{[14
]}

Devlin, Lisa ^{[15
]}

Dhalla, Fatima ^{[16
]}

Diwakar, Lavanya ^{[17
]}

Drewe, Elizabeth ^{[13
]}

Duncan, Christopher ^{[18
]}

Dziadzio, Magdalena ^{[19
]}

Elcombe, Suzanne ^{[20
]}

Elkhalifa, Shuayb ^{[21
]}

Gennery, Andrew ^{[22
,23
]}

Ghanta, Harichandrana ^{[24
]}

Goddard, Sarah ^{[17
]}

Grigoriadou, Sofia ^{[25
]}

Hackett, Scott ^{[26
]}

Hayman, Grant ^{[27
]}

Herriot, Richard ^{[28
]}

Herwadkar, Archana ^{[21
]}

Huissoon, Aarnoud ^{[8
]}

Jain, Rashmi ^{[16
]}

Jolles, Stephen ^{[29
]}

Johnston, Sarah ^{[11
]}

Khan, Sujoy ^{[30
]}

Laffan, James ^{[27
]}

Lane, Peter ^{[1
]}

Leeman, Lucy ^{[31
]}

Lowe, David M. ^{[6
,32
]}

Mahabir, Shanti ^{[33
]}

Mac Lochlainn, Dylan James ^{[16
]}

McDermott, Elizabeth ^{[13
]}

Misbah, Siraj ^{[16
]}

Moghaddas, Fiona ^{[11
]}

Morsi, Hadeil ^{[16
]}

Murng, Sai ^{[27
]}

Noorani, Sadia ^{[34
]}

O'Brien, Rachael ^{[35
]}

Patel, Smita ^{[16
]}

Price, Arthur ^{[33
]}

机构：

[1] Univ Birmingham, Inst Immunol & Immunotherapy, Clin Immunol Serv, Birmingham, W Midlands, England

[2] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England

[3] Leeds Teaching Hosp NHS Trust, Dept Clin Immunol & Allergy, St James Univ Hosp, Leeds, W Yorkshire, England

[4] Newcastle Univ, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England

[6] Royal Free London NHS Fdn Trust, Dept Immunol, London, England

[7] Royal Papworth NHS Fdn Trust, Cambridge, England

[8] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[9] Dudley Grp NHS Fdn Trust, Birmingham, W Midlands, England

[10] Sheffield Teaching Hosp NHS Fdn Trust, Clin Immunol & Allergy Dept, Sheffield, S Yorkshire, England

[11] North Bristol NHS Trust, Clin Immunol, Bristol, Avon, England

[12] Royal Infirm Edinburgh NHS Trust, Dept Haematol & Immunol, NHS Lothian, Edinburgh, Midlothian, Scotland

[13] Nottingham Univ Hosp NHS Trust, Clin Immunol & Allergy Dept, Nottingham, England

[14] Univ Coll London Hosp, Specialist Allergy & Clin Immunol, London, England

[15] Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland

[16] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England

[17] Royal Stoke Hosp, Dept Immunol, Stoke On Trent, Staffs, England

[18] Newcastle Univ, Translat & Clin Res Inst, Immun & Inflammat Theme, Newcastle Upon Tyne, Tyne & Wear, England

[19] UCL, Ear Inst, London, England

[20] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Reg Dept Clin Immunol & Allergy, Newcastle Upon Tyne, Tyne & Wear, England

[21] Salford Royal NHS Fdn Trust, Immunol Dept, Manchester, Lancs, England

[22] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[23] Great North Children S Hosp, Paediat Stem Cell Transplant Unit, Newcastle Upon Tyne, Tyne & Wear, England

[24] Univ Southampton, Univ Hosp Southampton NHS Trust, Dept Allergy & Clin Immunol, Southampton, Hants, England

[25] Barts Hlth NHS Trust, Immunol Dept, Royal London Hosp, London, England

[26] Univ Hosp Birmingham, Paediat Immunol Dept, Birmingham, W Midlands, England

[27] Epsom & St Helier Univ Hosp NHS Trust, Clin Immunol Serv, South West London Immunodeficiency Ctr, London, England

[28] Aberdeen Royal Infirm, Immunol Dept, Aberdeen, Scotland

[29] Univ Hosp Wales, Immunodeficiency Ctr Wales, Heath Pk, Cardiff, Wales

[30] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[31] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[32] UCL, Inst Immun & Transplantat, London, England

[33] Leicester Royal Infirm, Clin Immunol & Allergy Dept, Leicester, Leics, England

[34] Sandwell & West Birmingham Hosp NHS Trust, Clin Immunol Dept, Birmingham, W Midlands, England

[35] Frimley Pk Hosp, Dept Clin Immunol, Frimley, Surrey, England

[36] NHS Greater Glasgow & Clyde, Clin Immunol Serv, Glasgow, Lanark, Scotland

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2022年 / 209卷 / 03期

关键词：

COVID-19; SARS-CoV-2; hypogammaglobulinemia; inborn errors of immunity; primary immunodeficiencies; secondary immunodeficiencies; lymphopenia; COVID-19; IMMUNITY;

D O I：

10.1093/cei/uxac008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort. Individuals with immunodeficiency are at increased risk of severe infection. This study looks at outcomes following SARS-CoV-2 infection in 310 patients with primary or secondary immunodeficiency in the United Kingdom and finds significantly elevated mortality in both cohorts compared to the general population. Increasing age, pre-existing lymphopenia and other co-morbidities are identified as additional risk factors for death from COVID-19 in this cohort.

引用

页码：247 / 258

页数：12

共 50 条

[1] Secondary livedoid vasculopathy following SARS-CoV-2 infection
Carballido Vazquez, A. M.
Vega Lopez, T. L.
Manchado Lopez, P.
Martinez Garcia, G.
Mateos Mayo, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (05) : e368 - e370
[2] Secondary Polymyalgia Rheumatica Following SARS-CoV-2 Infection
Ocho, Kazuki
Hagiya, Hideharu
Ishikawa, Hisashi
Otsuka, Fumio
ACTA MEDICA OKAYAMA, 2024, 78 (06) : 465 - 468
[3] Thyrotoxicosis secondary to thyroiditis following SARS-CoV-2 infection
Coetzee, Ankia
Bhikoo, Raisa
Berndorfler, Bianca
Conradie, Wilhelmina
Taljaard, Jantjie J.
Conradie-Smit, Marli
JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2021, 26 (02) : 72 - 75
[4] Use and Outcomes of SARS-COV-2 Monoclonal Antibody Therapy in Patients with Primary Immunodeficiency
Monahan, Rose
Tang, Monica
Pham, Michele
JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S88 - S88
[5] Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency
Delavari, Samaneh
Abolhassani, Hassan
Abolnezhadian, Farhad
Babaha, Fateme
Iranparast, Sara
Ahanchian, Hamid
Moazzen, Nasrin
Nabavi, Mohammad
Arshi, Saba
Fallahpour, Morteza
Bemanian, Mohammad Hassan
Shokri, Sima
Momen, Tooba
Sadeghi-Shabestari, Mahnaz
Molatefi, Rasol
Shirkani, Afshin
Vosughimotlagh, Ahmad
Safarirad, Molood
Sharifzadeh, Meisam
Pashangzadeh, Salar
Salami, Fereshte
Shirmast, Paniz
Rezaei, Arezou
Shad, Tannaz Moeini
Mohraz, Minoo
Rezaei, Nima
Hammarstrom, Lennart
Yazdani, Reza
Aghamohamamdi, Asghar
JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (02) : 345 - 355
[6] Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency
Samaneh Delavari
Hassan Abolhassani
Farhad Abolnezhadian
Fateme Babaha
Sara Iranparast
Hamid Ahanchian
Nasrin Moazzen
Mohammad Nabavi
Saba Arshi
Morteza Fallahpour
Mohammad Hassan Bemanian
Sima Shokri
Tooba Momen
Mahnaz Sadeghi-Shabestari
Rasol Molatefi
Afshin Shirkani
Ahmad Vosughimotlagh
Molood Safarirad
Meisam Sharifzadeh
Salar Pashangzadeh
Fereshte Salami
Paniz Shirmast
Arezou Rezaei
Tannaz Moeini Shad
Minoo Mohraz
Nima Rezaei
Lennart Hammarström
Reza Yazdani
Asghar Aghamohamamdi
Journal of Clinical Immunology, 2021, 41 : 345 - 355
[7] Maternal and neonatal outcomes following SARS-CoV-2 infection
Boettcher, Lillian B.
Metz, Torri D.
SEMINARS IN FETAL & NEONATAL MEDICINE, 2023, 28 (01):
[8] Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients
Huang, Andy P.
Rey, Andrea Espina
Cherian, Christie G.
Livingston, Floyd R.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
[9] SARS-CoV-2 infection in patients with primary mitochondrial diseases: Features and outcomes in Italy
Mancuso, Michelangelo
La Morgia, Chiara
Valentino, Maria Lucia
Ardissone, Anna
Lamperti, Costanza
Procopio, Elena
Garone, Caterina
Siciliano, Gabriele
Musumeci, Olimpia
Toscano, Antonio
Primiano, Guido
Servidei, Serenella
Carelli, Valerio
MITOCHONDRION, 2021, 58 : 243 - 245
[10] SARS-CoV-2 infection in patients with primary Sjogren syndrome: characterization and outcomes of 51 patients
Brito-Zeron, Pilar
Melchor, Sheila
Seror, Raphaele
Priori, Roberta
Solans, Roser
Kostov, Belchin
Baldini, Chiara
Carubbi, Francesco
Luis Callejas, Jose
Guisado-Vasco, Pablo
Hernandez-Molina, Gabriela
Pasoto, Sandra G.
Valim, Valeria
Siso-Almirall, Antoni
Mariette, Xavier
Carreira, Patricia
Ramos-Casals, Manuel
RHEUMATOLOGY, 2021, 60 (06) : 2946 - 2957

← 1 2 3 4 5 →